Category: Oncotarget

Oncotarget News

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

May 24, 2023

we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].”BUFFALO, NY- May 24, 2023 – A new... read more

Figure 7: Schematic demonstrating the role of GPR141 in mediating breast cancer development and progression.

Oncotarget

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and The p-mTOR/p53 Axis

May 22, 2023

This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.”BUFFALO, NY- May 22, 2023 – A new research paper... read more

Figure 1: Inhibitors of mitochondrial respiration.

Oncotarget

Targeting Cellular Respiration as a Therapeutic Strategy in Glioblastoma

May 19, 2023

Here, we provide a brief overview of the status quo of targeting mitochondrial energy metabolism in glioblastoma and highlight a novel combination therapy.”BUFFALO, NY- May 19, 2023 – A new... read more

Oncotarget

Impact Journals at SSP 45th Annual Meeting

May 17, 2023

Impact Journals (Oncotarget's publisher) is proud to participate at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes May 31–June 2, 2023, in Portland, Oregon.BUFFALO, NY-May... read more

Figure 2: Polyclonal, Clonal and Restricted Repertoire Phenotypes in Clonality Testing.

Oncotarget

Automated, Accurate Reporting for NGS-Based Clonality Testing

May 16, 2023

we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.”BUFFALO, NY- May... read more

Figure 3: Combined analysis of kinase expression in tumors with cell line dependency to identify new gene targets. therapeutic targeting

Oncotarget

Using Cancer Proteomics Data to Identify Gene Candidates for Therapeutic Targeting

May 10, 2023

we consider some public molecular resources, including proteomics datasets, that may be leveraged to help identify gene candidates for therapeutic targeting in cancer.”BUFFALO, NY- May 10, 2023 – A new... read more

Oncotarget

Behind the Study: Role of Biomarkers in Management of Lumps in the Breast

May 10, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a recent research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the... read more

Figure 2: Comparison of human LY6 gene expression in normal uterine tissue (n = 146) to expression in uterine corpus endometrial carcinoma (n = 547).

Oncotarget

LY6 Gene Family: Potential Tumor Antigens and Prognostic Biomarkers in Endometrial Cancer

May 8, 2023

Importantly, the expression of several LY6 genes is elevated in UCEC [uterine corpus endometrial carcinoma] when compared to the expression in normal uterine tissue.”BUFFALO, NY- May 8, 2023 – A... read more

Oncotarget

Systemic AL Amyloidosis: Current Approach and Future Direction

May 5, 2023

AL amyloidosis is a fatal disease and systemic therapy is required to prevent deposition of amyloid in other organs and prevent progressive organ failure.”BUFFALO, NY- May 5, 2023 – A... read more

Figure 1: Retinol-mediated suppression of tumor-promoting IL-6 is disrupted in colon cancer-associated fibroblasts.

Oncotarget

Retinol Disruption and the Role of Vitamin A Metabolism in Colon Cancer

May 3, 2023

Retinoids are known to inhibit tumor-promoting IL-6 production.”BUFFALO, NY- May 3, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Disruption of... read more